Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by Analysts at StockNews.com
Analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock. Navidea Biopharmaceuticals Stock Performance Navidea Biopharmaceuticals stock opened at $0.04 on Friday. Navidea Biopharmaceuticals has a twelve month low of […]